DU
PRVB

Delphia (USA)’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Delphia (USA)’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-25,698
Closed -$103K – 450
2022
Q2 		$103K Buy
+25,698
New +$122K 0.07% 337

Other funds holding PRVB

SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Delphia (USA)'s PRVB Position: Q3 2022 in Review

Delphia (USA) sold out of Provention Bio, Inc. Common Stock (PRVB) in Q3 2022, closing a stake of 25,698 shares — an estimated $103K sold.

Delphia (USA) first reported a position in PRVB in Q2 2022 and held it in 1 quarter. The position peaked at $103K in Q2 2022. 112 funds tracked by Wall St. Rank hold PRVB as of Q3 2022.

  • Delphia (USA) reported no remaining Provention Bio, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Delphia (USA) sold 25,698 Provention Bio, Inc. Common Stock shares in Q3 2022, an estimated $103K.
  • Delphia (USA) first reported a position in Provention Bio, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • Delphia (USA)'s Provention Bio, Inc. Common Stock position peaked at $103K in Q2 2022.
  • 112 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q3 2022.

Based on Delphia (USA)'s 13F filing for Q3 2022, filed 14 Nov 2022.